Latest Insider Transactions at Artiva Biotherapeutics, Inc. (RTVA)
This section provides a real-time view of insider transactions for Artiva Biotherapeutics, Inc. (RTVA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Artiva Biotherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Artiva Biotherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Jennifer Bush COO, CLO, Secy, Compliance Off |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+40.72%
|
-
|
|
Sep 12
2024
|
Neha Krishnamohan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Sep 12
2024
|
Christopher Horan Chief Tech Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Sep 12
2024
|
Thorsten Graef Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Sep 12
2024
|
Heather Raymon SVP, Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
8,333,333
+46.11%
|
$99,999,996
$12.0 P/Share
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
461,687
+36.78%
|
$4,616,870
$10.2 P/Share
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,058,282
+50.0%
|
-
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Open market or private purchase
|
Indirect |
833,333
+41.35%
|
$9,999,996
$12.0 P/Share
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Other acquisition or disposition
|
Indirect |
461,687
+29.4%
|
$4,616,870
$10.2 P/Share
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Conversion of derivative security
|
Indirect |
1,058,284
+50.0%
|
-
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Open market or private purchase
|
Indirect |
416,666
+24.84%
|
$4,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Other acquisition or disposition
|
Indirect |
256,316
+23.3%
|
$2,563,160
$10.2 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Conversion of derivative security
|
Indirect |
354,972
+22.68%
|
-
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Open market or private purchase
|
Direct |
1,666,666
+33.51%
|
$19,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Other acquisition or disposition
|
Direct |
294,117
+15.2%
|
$2,941,170
$10.2 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Conversion of derivative security
|
Direct |
997,280
+29.67%
|
-
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Open market or private purchase
|
Direct |
416,666
+17.71%
|
$4,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Other acquisition or disposition
|
Direct |
461,687
+23.3%
|
-
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Conversion of derivative security
|
Direct |
1,058,284
+33.43%
|
-
|
|
Jul 22
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
BUY
Other acquisition or disposition
|
Direct |
49,019
+20.16%
|
$490,190
$10.2 P/Share
|
|
Jul 22
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
BUY
Conversion of derivative security
|
Direct |
145,089
+50.0%
|
-
|
|
Jul 22
2024
|
Yong Jun Huh |
BUY
Open market or private purchase
|
Indirect |
2,083,332
+29.18%
|
$24,999,984
$12.0 P/Share
|
|
Jul 22
2024
|
Yong Jun Huh |
BUY
Other acquisition or disposition
|
Indirect |
550,433
+19.25%
|
$5,504,330
$10.2 P/Share
|
|
Jul 22
2024
|
Yong Jun Huh |
BUY
Conversion of derivative security
|
Indirect |
1,352,252
+26.17%
|
-
|
|
Jul 22
2024
|
Fred Aslan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
228,905
+50.0%
|
-
|